CHICAGO (GenomeWeb) – Alexion Pharmaceuticals is teaming with sequencing and informatics startup Sema4 in an effort to improve diagnosis of rare diseases and speed drug discovery.

Sema4, a spinout from Mount Sinai Health System in New York, will bring its knowledge in next-generation sequencing and genome interpretation to Alexion's SmartPanel precision medicine platform, the two companies announced this morning.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.